- Novo Nordisk will present 35 abstracts at the EASD congress 2025 in Vienna.
- Semaglutide's impact on 'food noise' and body composition will be highlighted.
- Cagrilintide shows promise as a standalone obesity treatment in REDEFINE 1.
- Ozempic® outperforms dulaglutide in cardiovascular outcomes in the REACH study.
Overview
Novo Nordisk is set to present 35 abstracts at the European Association for the Study of Diabetes (EASD) congress 2025 in Vienna. The presentations will cover a range of topics within their diabetes and obesity portfolio, focusing on semaglutide and new obesity treatments.
Semaglutide Insights
The INFORM real-world evidence study highlights semaglutide's impact on reducing 'food noise', while the STEP UP clinical trial examines its effects on eating control and body composition post-weight loss. Additionally, the SOUL trial will discuss oral semaglutide's cardiovascular outcomes in high-risk type 2 diabetes patients.
New Obesity Treatments
Next-generation obesity treatment cagrilintide shows promise as a standalone therapy in the REDEFINE 1 study. Novo Nordisk will also present data on CagriSema, a combination of semaglutide and cagrilintide, and amycretin, a novel glucagon-like peptide-1 and amylin receptor agonist.
Comparative Studies
The REACH study, the first head-to-head real-world comparison, demonstrates the superiority of Ozempic® over dulaglutide in reducing cardiovascular events such as heart attacks and strokes. Other studies will explore semaglutide's effects on liver-related responses and its impact on hospitalisation rates in patients with type 2 diabetes and cardiovascular or kidney disease.
Event Details
Novo Nordisk will host an R&D investor event on 17 September to discuss the science and abstracts presented at the congress. The event will be accessible via a live webcast on their investor website.
